|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SMIM29 |
Gene summary for SMIM29 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SMIM29 | Gene ID | 221491 |
| Gene name | small integral membrane protein 29 | |
| Gene Alias | C6orf1 | |
| Cytomap | 6p21.31 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q86T20 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 221491 | SMIM29 | LZE2T | Human | Esophagus | ESCC | 9.54e-06 | 5.15e-01 | 0.082 |
| 221491 | SMIM29 | LZE4T | Human | Esophagus | ESCC | 9.53e-29 | 6.74e-01 | 0.0811 |
| 221491 | SMIM29 | LZE5T | Human | Esophagus | ESCC | 1.54e-04 | 2.52e-01 | 0.0514 |
| 221491 | SMIM29 | LZE7T | Human | Esophagus | ESCC | 3.42e-17 | 6.06e-01 | 0.0667 |
| 221491 | SMIM29 | LZE8T | Human | Esophagus | ESCC | 4.02e-05 | 1.78e-01 | 0.067 |
| 221491 | SMIM29 | LZE20T | Human | Esophagus | ESCC | 6.96e-12 | 3.71e-01 | 0.0662 |
| 221491 | SMIM29 | LZE22D1 | Human | Esophagus | HGIN | 1.90e-05 | 2.74e-01 | 0.0595 |
| 221491 | SMIM29 | LZE22T | Human | Esophagus | ESCC | 4.24e-14 | 7.57e-01 | 0.068 |
| 221491 | SMIM29 | LZE24T | Human | Esophagus | ESCC | 3.76e-31 | 6.89e-01 | 0.0596 |
| 221491 | SMIM29 | LZE21T | Human | Esophagus | ESCC | 2.35e-12 | 6.03e-01 | 0.0655 |
| 221491 | SMIM29 | LZE6T | Human | Esophagus | ESCC | 4.35e-10 | 3.97e-01 | 0.0845 |
| 221491 | SMIM29 | S014 | Human | Liver | HCC | 1.72e-35 | 9.77e-01 | 0.2254 |
| 221491 | SMIM29 | S015 | Human | Liver | HCC | 7.49e-39 | 1.09e+00 | 0.2375 |
| 221491 | SMIM29 | S016 | Human | Liver | HCC | 3.73e-38 | 9.43e-01 | 0.2243 |
| 221491 | SMIM29 | S027 | Human | Liver | HCC | 2.78e-14 | 6.01e-01 | 0.2446 |
| 221491 | SMIM29 | S028 | Human | Liver | HCC | 6.28e-29 | 9.11e-01 | 0.2503 |
| 221491 | SMIM29 | S029 | Human | Liver | HCC | 6.87e-29 | 9.66e-01 | 0.2581 |
| 221491 | SMIM29 | male-WTA | Human | Thyroid | PTC | 4.42e-19 | 2.49e-01 | 0.1037 |
| 221491 | SMIM29 | PTC01 | Human | Thyroid | PTC | 3.28e-16 | 3.46e-01 | 0.1899 |
| 221491 | SMIM29 | PTC04 | Human | Thyroid | PTC | 5.96e-08 | 2.20e-01 | 0.1927 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |